article thumbnail

Entry-Level Pharma Sales: It's More Than Just a Job Search (Here's Why)

Contrarian Sales Techniques

prescription drugs, medical devices), or specific companies. Utilize job boards: Explore dedicated job boards within the pharmaceutical industry, such as Pharmajobs, Medzilla, and BioSpace, alongside general job boards like LinkedIn and Indeed. This could include therapeutic areas (e.g., oncology, cardiology), product types (e.g.,

Sales 52
article thumbnail

Beating the Big C

Pharmaceutical Technology

.” While Pfizer is currently testing 18 medicines targeted against pancreatic, breast and lung cancers, figures released by the Pharmaceutical Research and Manufacturers of America [PhRMA] in April 2008 reveal that research companies are currently testing a record-breaking 750 experimental cancer drugs in America alone.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New legislation is a great first step to lower drug prices

World of DTC Marketing

KFF Tracking Poll found large majorities support allowing the federal government to negotiate and this support holds steady even after the public is provided the arguments being presented by parties on both sides of the legislative debate (83% total, 95% of Democrats, 82% of independents, and 71% of Republicans). Why did it happen?

article thumbnail

Trump’s lie on drug prices

World of DTC Marketing

But that law barred our government from negotiating for lower wholesale drug prices, which continued rising. According to the federal Centers for Medicaid and Medicare Services, our federal government spent $298 billion on prescription drugs at that time. It was a bizarre and fact-free claim, typical of Trumpian hyperbole.

article thumbnail

US Democrats’ blockbuster budget bill could spell big changes for drug prices

pharmaphorum

In addition to the climate provisions, however, the bill has a significant effect on prescription drug prices, and according to reports neither Manchin nor Sinema is objecting to these provisions, which are similar but not identical to the ones in the Build Back Better plan which previously passed in the House of Representatives.